Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
Broadly neutralizing human monoclonal JC polyomavirus VP1-specific antibodies as candidate therapeutics for progressive multifocal leukoencephalopathy.
Development of a recombinant immunotoxin for the immunotherapy of autoreactive lymphocytes expressing MOG-specific BCRs.
Personality in multiple sclerosis (MS): impact on health, psychological well-being, coping, and overall quality of life.
Interferon beta treatment of multiple sclerosis increases serum interleukin-7.
Neuro-Immune Interactions at Barrier Surfaces.
Leisure time activities of Iranian patients with multiple sclerosis: a qualitative study.
Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes.
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis ((DECIDE))
Dimethyl fumarate-associated lymphopenia: Risk factors and clinical significance.
The absence of 25-hydroxyvitamin D3-1α-hydroxylase potentiates the suppression of EAE in mice by ultraviolet light.
Two endogenous retroviral loci appear to contribute to Multiple Sclerosis.
Demyelination induces transport of ribosome-containing vesicles from glia to axons: evidence from animal models and MS patient brains.
Assessment of structural and functıonal vısual outcomes ın relapsıng remıttıng multıple sclerosıs wıth vısual evoked potentıals and optıcal coherence tomography.
Oligodendrocyte development and myelination in GFP-transgenic zebrafish.
Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta.
Patient trial of immunization to treat Alzheimer’s disease begins at Cedars-Sinai
The nature of genetic susceptibility to multiple sclerosis: constraining the possibilities.
Preclinical studies of sex differences: a clinical perspective.
Laquinimod in Relapsing-Remitting Multiple Sclerosis
Association of common mitochondrial DNA variants with multiple sclerosis and systemic lupus erythematosus.
The impact of sexual dysfunction on health-related quality of life in people with multiple sclerosis.
Selective immunomodulation by the antineoplastic agent mitoxantrone. I. Suppression of B lymphocyte function.
Dimethyl fumarate inhibits the expression and function of hypoxia-inducible factor-1α (HIF-1α).
More Than 15 Years of Experience with Intradetrusor OnabotulinumtoxinA Injections for Treating Refractory Neurogenic Detrusor Overactivity: Lessons to Be Learned.
A case of posterior reversible encephalopathy syndrome associated with gilenya(®) (fingolimod) treatment for multiple sclerosis.
Pages
« first
‹ previous
…
77
78
79
80
81
82
83
84
85
…
next ›
last »